SuperworthSherwin-Williams SHW
- Market cap
- $81.8B
- PE
- 31.1×
- 10y median 33.3×
- Forward PE
- 26.3×
- 10y median 26.5×
- Price to sales
- 3.4×
- EV/EBIT
- 22.8×
- Revenue, 12 months
- $24.4B
- +6% on a year ago
- Net margin
- 11.0%
- Free cash flow yield
- 3.9%
Sherwin-Williams trades at 31.1× trailing earnings, cheaper than 67% of the last ten years. Revenue was $24.4B over the last twelve months, up 6% on a year earlier with a 11% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $6.1B+1% | $5.3B+0% | $5.4B−1% | $6.3B+1% | $6.2B+1% | $5.3B+1% | $5.3B−1% | $6.3B+1% | $6.4B+3% | $5.6B+6% | $5.7B+7% | $6.8B+8% | |
| Cost of revenue | $3.2B−7% | $2.7B−10% | $2.8B−6% | $3.2B−5% | $3.1B−2% | $2.7B+1% | $2.7B−3% | $3.2B−0% | $3.2B+3% | $2.9B+6% | $2.9B+5% | $3.5B+8% |
| Gross profit | $2.9B+13% | $2.5B+14% | $2.5B+5% | $3.1B+7% | $3B+4% | $2.6B+1% | $2.6B+1% | $3.1B+2% | $3.1B+3% | $2.7B+5% | $2.8B+9% | $3.3B+7% |
| SG&A | $1.8B+9% | $1.9B+13% | $1.8B+6% | $1.8B+5% | $1.9B+8% | $1.9B+2% | $1.8B−0% | $2B+9% | $2B+3% | $1.9B+3% | $2B+10% | $2.1B+5% |
| $1.1B+11% | $641.7M+8% | $729.2M+2% | $1.3B+13% | $1.1B+3% | $698.2M+9% | $756.4M+4% | $1.1B−12% | $1.2B+4% | $778.7M+12% | $804.6M+6% | $1.2B+12% | |
| Interest expense | $101.9M+1% | $94.6M−13% | $103M−6% | $110.8M−1% | $103.4M+2% | $98.5M+4% | $103.8M+1% | $112.4M+1% | $117.2M+13% | $131.6M+34% | $131.6M+27% | $135.9M+21% |
| Pre-tax income | $1B+15% | $474M−4% | $640M+4% | $1.2B+16% | $1B+1% | $615.6M+30% | $653M+2% | $985.7M−16% | $1.1B+4% | $639M+4% | $679.8M+4% | $1.1B+13% |
| $247.5M+29% | $117.8M+9% | $134.8M−2% | $283.5M+30% | $216.6M−13% | $135.5M+15% | $149.1M+11% | $231M−19% | $227.4M+5% | $162.2M+20% | $145.1M−3% | $268.9M+16% | |
| Net income | $761.5M+11% | $356.2M−8% | $505.2M+6% | $889.9M+12% | $806.2M+6% | $480.1M+35% | $503.9M−0% | $754.7M−15% | $833.1M+3% | $476.8M−1% | $534.7M+6% | $843.6M+12% |
| $2.95+13% | $1.39−6% | $1.97+7% | $3.50+14% | $3.18+8% | $1.90+37% | $2.00+2% | $3.00−14% | $3.35+5% | $1.92+1% | $2.15+8% | $3.43+14% | |
| 258.4M−1% | 256.8M−2% | 255.8M−2% | 254.2M−2% | 253.9M−2% | 252.6M−2% | 252.5M−1% | 251.3M−1% | 249M−2% | 248.9M−2% | 248.1M−2% | 246M−2% |
Operating income: 72 periods, Q3 FY08 to Q2 FY26: not printed by the filing, worked out from its own lines.
EPS, diluted: 13 periods, Q2 FY08 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 18 periods, Q4 FY08 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q3 FY26 | $6.8B | $6.7B to $6.8B | $3.69 | $3.52 to $3.80 | 16 |
| Q4 FY26 | $5.9B | $5.8B to $5.9B | $2.36 | $2.30 to $2.46 | 15 |
| Q1 FY27 | $6B | $5.9B to $6.1B | $2.61 | $2.56 to $2.66 | 6 |
| Q2 FY27 | $7.1B | $7B to $7.2B | $4.16 | $4.08 to $4.22 | 6 |
| Q3 FY27 | $7.1B | $7B to $7.2B | $4.19 | $4.11 to $4.26 | 6 |
| Q4 FY27 | $6.1B | $6.1B to $6.2B | $2.71 | $2.65 to $2.75 | 6 |
| Q1 FY28 | $6.3B | $6.2B to $6.4B | $2.89 | $2.83 to $2.93 | 14 |
| Q2 FY28 | $7.5B | $7.3B to $7.6B | $4.69 | $4.60 to $4.77 | 14 |
Peers
Companies in Chemicals - Specialty nearest Sherwin-Williams' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| SHWSherwin-Williams | $81.8B | 31.1× | 33.3× | 26.3× | 3.4× | +6% | 11.0% |
| ECLEcolab | $80.9B | 38.7× | 37.3× | 33.5× | 4.8× | +7% | 12.6% |
| APDAir Products and Chemicals | $68.4B | n/m | 28.1× | 21.6× | 5.4× | +5% | −0.4% |
| LINLinde | $234.6B | 32.9× | 34.4× | 27.2× | 6.6× | +7% | 20.4% |
| PPGPPG Industries | $24.6B | 15.8× | 24.0× | 13.4× | 1.5× | +5% | 9.6% |
| IFFInternational Flavors & Fragrances | $24B | 82.6× | 35.5× | 27.3× | 2.4× | −5% | 2.9% |
| LYBLyondellBasell Industries | $21.5B | n/m | 9.2× | 9.2× | 0.7× | −2% | −1.1% |
| RPMRPM International | $12.6B | 18.3× | 25.5× | n/m | 1.6× | +6% | 8.7% |
| CLXClorox | $10.4B | 17.9× | 26.3× | n/m | 1.6× | −5% | 8.7% |
| Peer median | $24.3B | 25.6× | 27.2× | 24.4× | 2.0× | +5% | 8.7% |
Investors who own it
Investors we follow who held Sherwin-Williams at the end of Jun 30, 2026, from their 13F filings.
- Andreas HalvorsenViking Global Investors3.8% of portfolioadded
- Lee AinslieMaverick Capital1.8% of portfolioadded
- Dan SundheimD1 Capital Partners1.2% of portfolioadded
- Chase ColemanTiger Global Management0.4% of portfolio
- Tom GaynerMarkel Group0.2% of portfolio
More on Sherwin-Williams
Each number over time
- PE ratio
- Forward PE
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Dividend yield
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #5of 27Specialty chemicals stocks with the highest profit margins
- #10of 21Materials stocks with the fastest expected revenue growth
- #6of 12Specialty chemicals stocks with the fastest earnings growth
- #9of 13Specialty chemicals stocks cheapest against their own PE history
Its groups
About
- Industry
- Chemicals - Specialty
- Sector
- Basic Materials
Valuation data, not investment advice. Prices as of .